What Semaglutide is
Semaglutide is a GLP-1 receptor agonist that affects appetite, gastric emptying context, glucose-dependent insulin signaling, and metabolic regulation.
Semaglutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it changed the public conversation around pharmacologic weight loss and sits at the center of GLP-1 curiosity.
The useful starting point is to separate the molecule itself from the internet story around it. It became the mainstream peptide people associate with losing weight because food noise and appetite often change.
Why people keep looking it up
People know semaglutide as a GLP-1 drug for appetite reduction and weight loss.
Semaglutide activates GLP-1 receptors involved in appetite signaling, glucose-dependent insulin response, and metabolic regulation.
Semaglutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, appetite signaling, and glucose. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
This is an approved medicine for specific uses, but counterfeit, compounded, or research-labeled products do not automatically inherit that trust.
Large human clinical programs and official labels support specific approved uses. Other uses need separate source review.
Mechanistic evidence aligns with GLP-1 receptor pharmacology and incretin biology.
Why this page carries the current tier: Official approval, clinical trial programs, and current FDA safety communications.
The current seed trail for Semaglutide is pulling from 1 labels source, 1 regulatory source, 1 literature source, and 1 safety source.
Safety, limits, and regulatory context
Risks and contraindications should be read from current official labeling. Unapproved compounded or counterfeit products add quality and safety uncertainty.
FDA-approved semaglutide products exist for specific indications. FDA also warns about unapproved GLP-1 products marketed outside the approval pathway.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Semaglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Semaglutide is CID 56843331. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 56843331
- Formula
- C187H291N45O59
- Molecular weight
- 4114
- InChIKey
- DLSWIYLPEUIQAV-CCUURXOWSA-N
Matched synonyms include Semaglutide, 910463-68-2, Rybelsus, Ozempic, Wegovy, NN9535, NN 9535, NNC 0113-0217.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Semaglutide returns 671 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Semaglutide returns 4716 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- OZEMPIC, RYBELSUS
- Generic names
- ORAL SEMAGLUTIDE
- Routes
- ORAL
- Application numbers
- NDA213051
Indications and usage. 1 INDICATIONS AND USAGE RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are gluc...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including RYBELSUS or OZEMPIC tablets. Discontinue if pancreatitis is suspected. ( 5.2 ) • Diabetic Retinopathy Complications : Has been reported in a cardiovascular outcomes trial with semaglutide injection. Patients with a history of diabetic retinopathy should be monitored. ( 5.3 ) • Hypoglycemia...
Contraindications. 4 CONTRAINDICATIONS RYBELSUS and OZEMPIC tablets are contraindicated in patients with: • A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )] . • A prior serious hypersensitivity reaction to semaglutide or to any of the excipients in RYBELSUS or OZEMPIC tablets. Serious hypersensitivity reacti...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.